Table III.
Characterization of the first treatment.
| LPC, n=677 | ||||
|---|---|---|---|---|
|
|
||||
| Treatment characteristic | Non-high-risk, n=433 | High-risk, n=244 | LAPC, n=113 | Overall, n=790 |
| First treatment intention, n (%) | ||||
| Curative | 361 (83.4) | 208 (85.2) | 106 (93.8) | 675 (85.4) |
| Palliative | 5 (1.2) | 25 (10.2) | 4 (3.5) | 34 (4.3) |
| No treatment | 67 (15.5) | 11 (4.5) | 3 (2.7) | 81 (10.3) |
| First treatment, n (%) | ||||
| ADTb | 5 (1.4) | 25 (10.7) | 4 (3.6) | 34 (4.8) |
| Brachytherapy | 114 (31.1) | 16 (6.9) | 1 (0.9) | 131 (18.5) |
| Radical prostatectomy | 142 (38.8) | 38 (16.3) | 5 (4.5) | 185 (26.1) |
| Radiotherapy | 59 (16.1) | 36 (15.5) | 2 (1.8) | 97 (13.7) |
| Radiotherapy + HT | 46 (12.6) | 118 (50.6) | 98 (89.1) | 262 (37.0) |
| First management approacha, n (%) | ||||
| Bicalutamide | 0 (0.0) | 1 (0.4) | 0 (0.0) | 1 (0.1) |
| Goserelin | 4 (1.1) | 18 (7.7) | 4 (3.6) | 26 (3.7) |
| Orchidectomy | 1 (0.3) | 6 (2.6) | 0 (0.0) | 7 (1.0) |
| Brachytherapy | 114 (31.1) | 16 (6.9) | 1 (0.9) | 131 (18.5) |
| Radical prostatectomy | 87 (23.8) | 21 (9.0) | 4 (3.6) | 112 (15.8) |
| Radical prostatectomy + radiotherapy | 53 (14.5) | 17 (7.3) | 1 (0.9) | 71 (10.0) |
| Radical prostatectomy + radiotherapy + HT | 2 (0.5) | 0 (0.0) | 0 (0.0) | 2 (0.3) |
| Radiotherapy | 59 (15.8) | 36 (15.4) | 2 (1.8) | 97 (13.7) |
| Radiotherapy + HT | 46 (12.6) | 107 (45.9) | 83 (75.5) | 236 (33.3) |
| Radiotherapy + brachytherapy + HT | 0 (0.0) | 11 (4.7) | 15 (13.6) | 26 (3.7) |
a
Percentages calculated within patients treated with curative or palliative intention (non-high-risk LPC n=366, high-risk LPC n=233, LAPC n=110, overall n=709).
b
Includes bicalutamide, goserelin or orchidectomy. LPC, localised prostate cancer; LAPC, locally advanced prostate cancer; ADT, androgen deprivation therapy; HT, hormone therapy.